Adams et al. 2009. J Gene Med. 11(2):160-8. PMID: 19062185.
Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells.
Coulter et al. 2008. Gene Ther. 15(7):495-503. PMID: 18256696.
The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation.
McCarthy et al. 2007. J Gene Med. 9(6):511-20. PMID: 17471586.
Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.
McCarthy et al. 2007. Gene Ther. 14(3):246-55. PMID: 17006546.
p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy.
Worthington et al. 2002. Gene Ther. 9(4):263-9. PMID: 11896465.
Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy.